{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 38,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/32",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.72,
        "w": 0.09,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59fa8c49-e029-45d0-b3b7-d319dcf6aa5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.14,
        "y": 0.48
      },
      "kind": "list",
      "text": "Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiating three Phase 1/2 clinical trials with Olvi-Vec and ELIAS Animal Health (global rights) initiating canine efficacy studies with V-VET1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68d5ca35-5e87-4b81-aa31-4b71afec53b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.14,
        "y": 0.78
      },
      "kind": "list",
      "text": "Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a342b3f5-0b44-4de9-a017-c548914bfbc2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.14,
        "y": 0.65
      },
      "kind": "list",
      "text": "Focused Commercial Strategy. US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b424c59a-4056-487a-bc2e-25728ce911c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.14,
        "y": 0.18
      },
      "kind": "list",
      "text": "Olvi-Vec: De-risked late-stage Clinical Program. Ongoing pivotal trial in late-stage Ovarian Cancer and planned Phase 2 trial Adjuvant Maintenance NSCLC",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c960af64-69b4-44c7-a2bd-a58819b469fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.14,
        "y": 0.33
      },
      "kind": "list",
      "text": "CHOICE™ Platform; Broad and Diverse Discovery Engine. Library with over 500 novel vaccinia strains and 110+ transgenes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce643764-fe21-4255-8216-94f8247b90f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Highlights of Genelux Execution",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e195d779-80de-4225-ae59-b05a03b72548",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5de6dc66-9db0-485c-9cb3-90916a0b13a8",
      "evidence": "list/bullet: Validating Strategic Partnerships. Newsoara Biopharma (Greater China rights) initiating three Phase 1/2 clinical trials with Olvi-Vec and ELIAS Animal Health (global rights) initiating canine efficacy studie",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}